A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 117,600 shares of BMEA stock, worth $756,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,600
Previous 110,700 6.23%
Holding current value
$756,168
Previous $498,000 138.35%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.23 - $10.1 $29,187 - $69,690
6,900 Added 6.23%
117,600 $1.19 Million
Q2 2024

Aug 14, 2024

BUY
$4.14 - $15.3 $458,297 - $1.69 Million
110,700 New
110,700 $498,000
Q4 2023

Feb 14, 2024

SELL
$8.37 - $19.8 $2.07 Million - $4.89 Million
-247,100 Reduced 80.54%
59,700 $866,000
Q3 2023

Nov 14, 2023

BUY
$13.44 - $23.02 $4.12 Million - $7.06 Million
306,800 New
306,800 $4.22 Million

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $188M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.